Related Experiment Videos
Antiangiogenic effects of somatostatin analogues
N García de la Torre1, J A H Wass, H E Turner
1Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK.
Abstract:
Inhibition of angiogenesis has become a target for antineoplastic therapy and for treatment of retinal neovascularization. The presence of somatostatin receptors on tumour cells and on the proliferating vascular endothelium has led to several in vitro and in vivo studies to investigate the antiproliferative and antiangiogenic effects of somatostatin analogues. Currently available data suggest that somatostatin analogues might inhibit angiogenesis directly through somatostatin receptors present on endothelial cells and also indirectly through the inhibition of growth factor secretion such as IGF-I and vascular endothelial growth factor (VEGF) and reducing monocyte chemotaxis. However, beneficial effects on inhibition of neovascularization have been questioned by some studies. More work is therefore required to firmly establish the role of somatostatin analogues as potential antiangiogenic therapy. The currently available somatostatin analogues have high affinity for somatostatin receptor subtype 2 (sst2) and, to a lesser extent, sst5 and sst3. However, because vascular endothelial cells express several types of somatostatin receptors, it will be important to investigate somatostatin analogues with different receptor subtype affinities, which might increase the spectrum of available therapy for tumours.
Insights
Somatostatin analogues show potential for inhibiting tumor growth and retinal neovascularization by targeting angiogenesis. Further research is needed to confirm their effectiveness and explore analogues with varied receptor affinities for enhanced cancer therapy.
Area of Science:
- Oncology
- Vascular Biology
- Endocrinology
Background:
- Angiogenesis inhibition is a key strategy for antineoplastic therapy and treating retinal neovascularization.
- Somatostatin receptors are present on tumor cells and vascular endothelium, prompting investigation into somatostatin analogues' effects.
- Existing data suggest somatostatin analogues may inhibit angiogenesis directly and indirectly by affecting growth factors and monocyte chemotaxis.
Purpose of the Study:
- To investigate the antiproliferative and antiangiogenic effects of somatostatin analogues.
- To evaluate the potential of somatostatin analogues in cancer and retinal neovascularization therapies.
- To explore the role of somatostatin receptor subtypes in mediating these effects.
Main Methods:
- In vitro and in vivo studies were conducted.
- Analysis of somatostatin analogues' effects on endothelial cells and growth factor secretion (IGF-I, VEGF).
- Investigation of somatostatin receptor subtype affinities (sst2, sst5, sst3).
Main Results:
- Somatostatin analogues show potential antiproliferative and antiangiogenic effects.
- Mechanisms include direct action on endothelial somatostatin receptors and indirect inhibition of growth factors.
- Some studies question the beneficial effects on neovascularization, indicating a need for more research.
Conclusions:
- Somatostatin analogues may inhibit angiogenesis, offering a potential therapeutic avenue.
- Further research is required to establish their definitive role in antiangiogenic therapy.
- Investigating analogues with diverse somatostatin receptor affinities could broaden therapeutic options for tumors.